Recent advances in the pathogenesis and immunotherapy of multiple sclerosis;Fortschritte im verständnis von pathogenese und immuntherapie der multiplen sklerose

Nervenarzt

Volumn 78, Issue SUPPL. 1, 2007, Pages 15-26

  Gold, R ^a   Rieckmann, P ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Immunotherapy; Interferon; Molecular pathology; Neuroprotection

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; DACLIZUMAB; FUMARIC ACID; GLATIRAMER; GLUCOCORTICOID; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB;

CONFERENCE PAPER; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG PULSE THERAPY; GLIA; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NERVE CELL; NERVE DEGENERATION; PATHOGENESIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CEREBRAL CORTEX; CLINICAL TRIALS AS TOPIC; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERFERON-BETA; MITOXANTRONE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE FIBERS, MYELINATED; NEURONS; NEUROPROTECTIVE AGENTS; OLIGODENDROGLIA; PEPTIDES; RECOMBINANT PROTEINS;

EID: 36248975222     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2327-8     Document Type: Conference Paper

References (57)

1. Aboul-Enein F, Rauschka H, Kornek B et al. (2003) Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 62: 25-33
2. Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7: 115-121
3. Weinshenker BG, O'Brien PC, Petterson TM et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46: 878-886
4. Keegan M, Konig F, McClelland R et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366: 579-582
5. Bassetti C, Beer K, Beer S et al. (2006) Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006) Nervenarzt 77: 1506-1518
6. Lucchinetti CF, Mandler RN, McGavern D et al. (2002) A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125: 1450-1461
7. Lennon VA, Wingerchuk DM, Kryzer TJ et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112
8. Schilling S, Linker R, Konig F et al. (2006) Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses. Clinical experience with 16 patients. Nervenarzt 77: 430-438
9. Zhou D, Srivastava R, Nessler S et al. (2006) Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 103: 19057-19062
10. Rieckmann P, Maurer M (2002) Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis. Curr Opin Neurol 15: 361-370
11. Patrikios P, Stadelmann C, Kutzelnigg A et al. (2007) Remyelination is extensive in a subset of multiple sclerosis patients. Brain 130: 879
12. Kuhlmann T, Lingfeld G, Bitsch A et al. (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125: 2202-2212
13. Peterson JW, Bo L, Mork S et al. (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50: 389-400
14. Bo L, Vedeler CA, Nyland H et al. (2003) Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 9: 323-331
15. Merkler D, Ernsting T, Kerschensteiner M et al. (2006) A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 129: 1972-1983
16. Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 55: 458-468
17. Cepok S, Zhou D, Srivastava R et al. (2005) Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 115: 1352-1360
18. Serafini B, Rosicarelli B, Magliozzi R et al. (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14: 164-174
19. Berger T, Rubner P, Schautzer F et al. (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349: 139-145
20. Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971
21. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192: 393-404
22. Skulina C, Schmidt S, Dornmair K et al. (2004) Multiple sclerosis: Brain-infiltrating CD8(+) T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A 101: 2428-2433
23. Hohlfeld R, Wekerle H (2005) Drug Insight: using monoclonal antibodies to treat multiple sclerosis. Nat Clin Pract Neurol 1: 34-44
24. Kerschensteiner M, Gallmeier E, Behrens L et al. (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189: 865-870
25. Stadelmann C, Kerschensteiner M, Misgeld T et al. (2002) BDNF and gp145trkB in multiple sclerosis brain lesions: Neuroprotective interactions between immune and neuronal cells? Brain 125: 75-85
26. Linker R, Lee DH, Siglienti I et al. (2007) Is there a role for neurotrophins in the pathology of multiple sclerosis? J Neurol (Suppl 1) 254: I33-I40
27. Linker RA, Maurer M, Gaupp S et al. (2002) CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8: 620-624
28. Giess R, Maurer M, Linker R et al. (2002) Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol 59: 407-409
29. Grauer O, Offenhausser M, Schmidt J et al. (2001) Glucocorticosteroid therapy in optic neuritis and multiple sclerosis: evidence from clinical studies and practical recommendations. Nervenarzt 72: 577-589
30. Ruprecht K, Klinker E, Dintelmann T et al. (2004) Plasma exchange for severe optic neuritis - Treatment of 10 patients. Neurology 63: 1081-1083
31. Kappos L, Polman CH, Freedman MS et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242-1249
32. Buttmann M, Rieckmann P (2007) Interferon-beta1b in multiple sclerosis. Exp Rev Neurother 7: 227-239
33. Pohl D, Rostasy K, Gartner J et al. (2005) Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 64: 888-890
34. Sandberg-Wollheim M, Frank D, Goodwin TM et al. (2005) Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 65: 802-806
35. Goodin DS, Frohman EM, Garmany GP et al. (2002) Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58: 169-178
36. Clanet M, Radue EW, Kappos L et al. (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59: 1507-1517
37. Panitch H, Goodin DS, Francis G et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS - The EVIDENCE trial. Neurology 59: 1496-1506
38. Schwid SR, Thorpe J, Sharief M et al. (2005) Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol 62: 785-792
39. Durelli L, Verdun E, Barbero P et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) Lancet 359: 1453-1460
40. Koch-Henriksen N, Sorensen PS, Christensen T et al. (2006) A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 66: 1056-1060
41. Sorensen PS, Koch-Henriksen N, Ross C et al. (2005) Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65: 33-39
42. Sorensen PS, Ross C, Clemmesen KM et al. (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362: 1184-1191
43. Ford CC, Johnson KP, Lisak RP et al. (2006) A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 12: 309-320
44. Haas J, Firzlaff M (2005) Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone) Eur J Neurol 12: 425-431
45. Vallittu AM, Peltoniemi J, Elovaara I et al. (2005) The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurol Scand 112: 234-237
46. Ziemssen T, Kumpfel T, Schneider H et al. (2005) Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. J Neurol Sci 233: 109-112
47. Chan A, Weilbach FX, Toyka KV et al. (2005) Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 139: 152-158
48. Hartung HP, Gonsette R, Konig N et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360: 2018-2025
49. Ramtahal J, Jacob A, Das K et al. (2006) Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 253: 1160-1164
50. Miller DH, Khan OA, Sheremata WA et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15-23
51. Polman CH, O'Connor PW, Havrdova E et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910
52. Yousry TA, Major EO, Ryschkewitsch C et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924-933
53. Kappos L, Antel J, Comi G et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124-1140
54. Metz I, Lucchinetti CF, Openshaw H et al. (2007) Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 130: 1254-1262
55. Romine JS, Sipe JC, Koziol JA et al. (1999) A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Phys 111: 35-44
56. O'Connor PW, Li D, Freedman MS et al. (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894-900
57. Polman C, Barkhof F, Sandberg-Wollheim M et al. (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64: 987-991